Aurobindo Pharma Ltd has received final approval from the US Food & Drug Administration to manufacture and market Levofloxacin Injection.
Levofloxacin injection is the generic equivalent of Janssen Pharmaceuticals Inc’s Levaquin injection. It is indicated for the treatment of adults with mild, moderate, and severe infections caused by susceptible isolates of the designated micro-organisms such as pneumonia.
The product would be marketed and sold by the Hyderabad-based company’s US subsidiary AuroMedics Pharma LLC, according to a release.